The sales of obstructive airway diseases medicines in Canada are forecasted to show a steady year-on-year growth from 2024 to 2028, ranging from 43.8 USD in 2024 to 47.9 USD PPP per capita in 2028. This indicates consistent annual growth rates around 2.2%. The compounded annual growth rate (CAGR) over this five-year period is approximately 2.1%. In 2023, sales were approximately 42.9 USD PPP per capita.
Future trends to watch for include the impact of emerging technologies in personalized medicine, which could influence treatment protocols and, consequently, market dynamics. Additionally, the regulatory landscape might evolve, affecting drug approval processes and market access.
